Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
2(50.0%)
Phase 2
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 4(2)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07232966Phase 3Not Yet Recruiting

Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension

Role: lead

NCT04135911Suspended

A Prospective Study on The"Management of Hypertension in Young and Middle-aged Subjects in Enterprises Setting"

Role: lead

NCT05089448Phase 4Recruiting

Morning Versus Bedtime Dosing of Antihypertensive Medication

Role: lead

NCT03547856Recruiting

A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"

Role: lead

NCT02893358Phase 4Completed

Antihypertensive Treatment in Masked Hypertension

Role: lead

NCT03457467Phase 2Unknown

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Role: lead

NCT01466699Unknown

The Study of Blood Pressure Variability to Impact Arterial Stiffness and Carotid Atherosclerosis

Role: lead

All 7 trials loaded